GLP-1 cost in 2026: semaglutide, tirzepatide, brand vs. compounded — full comparison

Two molecules, many price tiers

GLP-1 medications available for weight management in 2026 fall into two molecular categories: semaglutide (in Wegovy, Ozempic, and compounded semaglutide programs) and tirzepatide (in Zepbound, Mounjaro, and compounded tirzepatide programs). Tirzepatide activates both GIP and GLP-1 receptors, which produced modestly stronger weight loss on average in clinical trials. It also costs slightly more in most pathways. The decision between them is as much about cost and access as it is about mechanism.

Compounded options: the cheapest GLP-1 pathway

Compounded semaglutide from a 503A pharmacy via telehealth remains the cheapest GLP-1 option available for cash-pay patients. Prices start around $150 a month all-in (Fridays) and range up to $297 a month at higher doses. Compounded tirzepatide starts slightly higher — around $199 a month all-in (Curex) through $449 a month at the high end (Willow).

Both operate today under a 503A individual-patient pathway — not the broad shortage-era compounding that existed in 2023–2024. Confirm with any provider how they document the individual clinical basis for compounding before you enroll.

Semaglutide vs tirzepatide compounded cost comparison

• Cheapest compounded semaglutide starter: ~$150/mo (Fridays).
• Cheapest compounded tirzepatide starter: ~$199/mo (Curex).
• Mid-tier compounded semaglutide all-in: ~$178/mo (Mochi) or ~$197/mo (Henry Meds).
• Mid-tier compounded tirzepatide all-in: ~$278/mo (Mochi) or ~$349/mo (Henry Meds).
• The cost premium for tirzepatide over semaglutide averages $50–$100/mo at comparable doses and providers.

Brand self-pay programs: competitive with compounded at some tiers

Both Novo Nordisk and Eli Lilly have introduced self-pay programs that undercut retail pharmacy prices significantly. For the starter dose, brand-name self-pay is now within range of mid-tier compounded programs.

NovoCare Wegovy: $199 → $349/mo

Novo Nordisk's direct self-pay program offers Wegovy at $199 introductory, then $349 ongoing. For women who specifically want FDA-approved brand semaglutide without insurance, this is the best pathway — and at the introductory rate it competes with some compounded programs. The $349 ongoing rate is more expensive than Mochi or Fridays but represents branded Wegovy directly from the manufacturer.

LillyDirect Zepbound: $299–$449/mo

Lilly's direct vial program offers brand-name, FDA-approved Zepbound at $299 a month for 2.5mg, $399 for 5mg, $449 for 7.5–15mg. The 45-day refill window is important fine print — missing it causes a jump to standard pharmacy pricing. At the starter dose, LillyDirect is $100/mo more than the cheapest compounded tirzepatide and $100/mo more than NovoCare's semaglutide introductory rate.

With insurance: savings cards change everything

If your commercial insurance covers Wegovy or Zepbound, the manufacturer savings cards cap monthly costs at approximately $25 a month — transforming an expensive medication into a manageable prescription cost. Eligibility requires qualifying commercial insurance (not Medicare, Medicaid, or government plans) with actual coverage for the obesity indication.

Getting there involves: confirming your plan covers the drug, getting a prior authorization (BMI criteria, comorbidity documentation, often prior lifestyle treatment), and enrolling in the savings card. Many initial insurance denials are reversed on the first appeal — it's worth the effort given the $25 vs. $1,000+ monthly difference.

Why GLP-1 costs matter more in perimenopause

Perimenopausal weight changes are driven by hormonal shifts — estrogen decline worsening insulin resistance, redistributing fat toward the abdomen, and disrupting GLP-1 and leptin appetite signals. These metabolic changes can make GLP-1 therapy particularly effective during the transition. Several menopause-specialist clinicians now combine GLP-1 medications with HRT, recognizing that addressing both the hormonal root and the metabolic consequence produces better outcomes than either alone.

The cost consideration becomes part of a longer-term conversation: GLP-1 medications are not short courses. Most benefit requires sustained use. Understanding the 12-month cost of each pathway — not just the introductory monthly rate — is essential before committing.

Annual cost by pathway

• With commercial insurance + savings card ($25/mo): $300/year.
• Fridays compounded semaglutide ($150–$249/mo): $1,800–$2,988/year.
• Mochi Health semaglutide all-in (~$178/mo): ~$2,136/year.
• NovoCare Wegovy ongoing ($349/mo): ~$4,188/year.
• Curex compounded tirzepatide (~$199/mo): ~$2,388/year.
• Mochi Health tirzepatide all-in (~$278/mo): ~$3,336/year.
• LillyDirect Zepbound starter ($299/mo): ~$3,588/year.
• LillyDirect Zepbound maintenance ($449/mo): ~$5,388/year.
• Retail pharmacy without discounts: $13,032–$16,200/year.